Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 9, Pages 1924-1932
Publisher
Springer Science and Business Media LLC
Online
2022-08-23
DOI
10.1038/s41591-022-01953-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
- (2022) Boris Julg et al. NATURE MEDICINE
- Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
- (2022) Bryan T. Mayer et al. PLoS Computational Biology
- Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
- (2021) Yunda Huang et al. EBioMedicine
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
- (2021) Lawrence Corey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amping up HIV antibodies
- (2021) Dennis R. Burton SCIENCE
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- (2021) Kristen A. Earle et al. VACCINE
- Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
- (2021) Yunda Huang et al. Human Vaccines & Immunotherapeutics
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
- (2021) Kathryn E. Stephenson et al. NATURE MEDICINE
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
- (2021) Emmanuel B. Walter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Broadly Neutralizing Antibodies for HIV Prevention
- (2020) Shelly T. Karuna et al. Annual Review of Medicine
- Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials
- (2020) Daniel B. Reeves et al. PLoS Computational Biology
- Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
- (2020) Kathryn E. Stephenson et al. Annual Review of Immunology
- A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results
- (2019) Christopher D. Pilcher et al. AIDS
- Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials
- (2019) Peter B. Gilbert et al. STATISTICS IN MEDICINE
- A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge
- (2019) Amarendra Pegu et al. Cell Host & Microbe
- Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
- (2019) Yehuda Z. Cohen et al. PLoS One
- Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool
- (2019) Eduard Grebe et al. BMC INFECTIOUS DISEASES
- The complex challenges of HIV vaccine development require renewed and expanded global commitment
- (2019) Linda-Gail Bekker et al. LANCET
- Brief Report
- (2019) Yunda Huang et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
- (2018) Martin R. Gaudinski et al. PLOS MEDICINE
- Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
- (2018) Kshitij Wagh et al. PLoS Pathogens
- Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
- (2018) Matthias G. Pauthner et al. IMMUNITY
- Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults
- (2017) Yunda Huang et al. mAbs
- Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
- (2017) Kenneth H. Mayer et al. PLOS MEDICINE
- Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
- (2016) Kshitij Wagh et al. PLoS Pathogens
- Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
- (2015) Nathan I. Nicely et al. EBioMedicine
- HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
- (2014) Justin Pollara et al. JOURNAL OF VIROLOGY
- Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
- (2013) Marcella Sarzotti-Kelsoe et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Nomenclature for Immune Correlates of Protection After Vaccination
- (2012) S. A. Plotkin et al. CLINICAL INFECTIOUS DISEASES
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
- (2012) Barton F. Haynes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating time since infection in early homogeneous HIV-1 samples using a poisson model
- (2010) Elena E Giorgi et al. BMC BIOINFORMATICS
- Correlates of Protection Induced by Vaccination
- (2010) S. A. Plotkin Clinical and Vaccine Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started